Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 20 mg injection every 2 weeks
TASP_SC_20MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.66 (0.01 to 48.67) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.68 (2.78 to 11.52) | 0.21 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.30 (4.47 to 27.80) | 0.12 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.77 (1.10 to 6.78) | 0.28 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.92 (0.05 to 14.58) | 0.46 |